ASCO 2020 Top 12” #10: Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax In short videos with accompanying text, Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of... June 26, 20202019 ConferencesBy Brad Hedrick
ASCO 2020 Top 12” #11: Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) In short videos with accompanying text, Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of... June 26, 20202019 ConferencesBy Brad Hedrick
ASCO 2020 Top 12” #12: The shift in therapies for the treatment of CLL patients in the US Veterans Health Administration (VHA) from 2013-2018 In short videos with accompanying text, Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of... June 26, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients... June 24, 20202019 Conferences, MRD & Disease MonitoringBy Brad Hedrick
ASH 2019: Dr. Alexey Danilov on T cell function in chronic lymphocytic leukemia (CLL) Dr. Alexey Danilov on T cell function in chronic lymphocytic leukemia (CLL)... June 19, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more. ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding... June 15, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Wiestner Discusses a New Approach to Stopping Bruton’s Tyrosine Kinase (BTK) ASH 2019: Dr. Wiestner Discusses a Novel Way to Control CLL by Degrading BTK Rather Than Blocking It.... June 8, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Lindsey Roeker on Stem Cell Transplants for chronic lymphocytic leukemia (CLL) At ASH 2019, Dr. Roeker discussed new research on the role of stem cell transplants in treating CLL.... June 1, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Alexey Danilov and Dr. John Pagel discuss New Drug Targeting SYK Pathway Provides Hope When Used in Combination with Obinutuzumab ASH 2019: Dr. Alexey Danilov and Dr. John Pagel discuss New Drug Targeting SYK Pathway Provides Hope When Used in... May 22, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Choi Discusses a Cirmtuzumab and Ibrutinib Phase I/II Clinical Trial In this interview, Dr. Choi discusses updates contained in an abstract he presented at ASH 2019 entitled: Cirmtuzumab, a ROR1... May 18, 20202019 ConferencesBy Brad Hedrick
